Latest Amag Pharmaceuticals (AMAG) Headlines
Concise Analysis of the International Intravenous (IV) Iron Drugs Industry
M2 - Tue Mar 11, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8bxct/intravenous_iv) has announced the addition of the "Concise Analysis of the International Intravenous (IV) Iron Drugs Industry" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 20 companies including many key and niche players such as: - Actavis, Inc. - AMAG Pharmaceuticals, Inc. - Fresenius Medical Care AG & Co. - KGaA Galenica Ltd. - Vifor Pharma Ltd. - Luitpold Pharmaceuticals, Inc. - American Regent, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview & Trends 3. Regulatory Overview 4. Overview Of Intravenous (Iv) Iron Drugs 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 20 (including Divisions/Subsidiaries - 22) - The United States (8) - Japan (2) - Europe (4) - Germany (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (8) For more information visit http://www.researchandmarkets.com/research/k8...avenous_iv
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Shares of AMAG Down 12.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 9:33AM CST
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 4 months, AMAG Pharmaceuticals has returned 12.64% as of today's recent price of $21.11.
AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 34th Annual Healthcare Conference
GlobeNewswire - Thu Feb 27, 8:52AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Cowen and Company 34 Annual Healthcare Conference on Monday, March 3, 2014 at 4:10 p.m. ET in Boston. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed.
AMAG Pharmaceuticals names Edward Jordan as SVP of Sales and Marketing
M2 - Wed Feb 26, 3:16AM CST
Pharmaceutical company AMAG Pharmaceuticals (NasdaqGS:AMAG) reported on Tuesday the election of Edward Jordan as senior vice president of its sales and marketing.
AMAG Pharmaceuticals Appoints Edward Jordan as Senior Vice President of Sales and Marketing
GlobeNewswire - Tue Feb 25, 7:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Edward Jordan as senior vice president of sales and marketing. Mr. Jordan brings to AMAG more than 20 years of experience in U.S. and international pharmaceutical sales and marketing operations. Prior to joining AMAG, Mr. Jordan served as head of sales, marketing, and operations of the women's health division at Teva Pharmaceuticals. In this role he led sales, marketing, training, and sales analytics for their branded pharmaceuticals, over-the-counter products and a medical device.
Mintz Levin Named Biotechnology "Law Firm of the Year- North America" by M&A Today Global Awards
Business Wire - Fri Feb 21, 11:46AM CST
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. announced that it has been recognized by M&A Today's Global Awards as the 2014 "Law Firm of the Year (Biotechnology) - North America." M&A Today's Global Awards program identifies "industry leaders, exemplary teams and distinguished organizations, based on the simple principles of veracity, accuracy and insight."
Study Shows MuGard(R) is More Effective Than Sham-Control at Reducing Mouth and Throat Soreness Associated With Oral Mucositis in Head and Neck Cancer Patients
GlobeNewswire - Tue Feb 18, 7:01AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the publication of data from a multi-institutional trial of MuGard in the online edition of the journal Cancer available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. MuGard is a mucoadhesive hydrogel. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing pain associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.
AMAG Pharmaceuticals Has Returned 19.9% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Thu Feb 13, 9:24AM CST
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 3 months, AMAG Pharmaceuticals has returned 19.93% as of today's recent price of $19.35.
Spanning and CloudLock to Present "How to Prevent Data Loss and Ensure Compliance for Your SaaS Applications"
Business Wire - Thu Feb 13, 8:00AM CST
Spanning Cloud Apps, the leading provider of data backup and recovery for cloud applications, will join CloudLock, the cloud security pioneer and the world's leading cloud data security company, to demonstrate how organizations can proactively take control of their SaaS applications, preventing data loss and maintaining security and compliance. The webinar, "How to Prevent Data Loss and Ensure Compliance for Your SaaS Applications," will feature AMAG Pharmaceuticals. The company will explain how they effectively implemented backup and recovery for Google Apps and are enforcing data loss prevention policies in Google Drive. Attendees will learn how to mitigate the risks of data leakage and loss, while improving business continuity.
AMAG Pharmaceuticals (AMAG) Falls: Crumbles 5.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:38AM CST
AMAG Pharmaceuticals, Inc. (AMAG) saw a big move last session, as the company’s shares fell by more than 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for AMAG, as the stock is now down roughly 13% since Jan 15.
AMAG Pharmaceuticals Announces Pricing of $175 Million of 2.50% Convertible Senior Notes Due 2019
GlobeNewswire - Wed Feb 12, 5:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the pricing of $175 million aggregate principal amount of 2.50% Convertible Senior Notes due 2019 (the "notes") in an underwritten public offering (the "offering") registered under the Securities Act of 1933, as amended. The size of the transaction was increased from the previously announced aggregate principal amount of $150 million. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as book-running managers and Cowen and Company, LLC and Robert W. Baird & Co. Incorporated are acting as co-managers for the offering. AMAG has granted the underwriters the option to purchase, exercisable within a 30-day period, up to an additional $25 million principal amount of notes solely to cover over-allotments, if any. The offering is expected to close on February 14, 2014, subject to customary closing conditions.
Survey Says: Voicemail-to-Text Service Brings the Speed and Convenience to Voice Messaging that Consumers Want
Business Wire - Tue Feb 11, 7:00AM CST
Nuance Communications, Inc. (NASDAQ:NUAN) today announced the results of a recently commissioned third-party survey conducted by Research Now that explores text messaging and voicemail habits of mobile smartphone users. Taking a closer look at how people prefer to stay in touch, the survey revealed that users are seeking ways to ensure their messages are received promptly every time for both text and voice messaging. The survey revealed that, given a choice, 62 percent of people would most likely switch to a voice-to-text messaging system from a traditional voicemail system to stay better connected on the go.
AMAG Pharmaceuticals Announces Proposed Offering of $150 Million of Convertible Senior Notes due 2019
GlobeNewswire - Mon Feb 10, 3:07PM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of Convertible Senior Notes due 2019 (the "notes") in an underwritten public offering (the "offering") registered under the Securities Act of 1933, as amended. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as book-running managers for the offering. AMAG expects to grant the underwriters an option to purchase, exercisable within a 30-day period, up to an additional $22.5 million principal amount of notes, solely to cover over-allotments, if any.
AMAG Pharmaceuticals, Inc. to Participate in the Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 10, 8:39AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will participate in an analyst-led fireside chat at the Leerink Global Healthcare Conference in New York, NY. The fireside chat will take place on Wednesday, February 12, 2014 at 8:00 a.m. ET and will include a discussion on the company's business, regulatory status, strategy and growth prospects.
Wider-than-Expected Q4 Loss at AMAG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 9:40AM CST
AMAG's fourth quarter 2013 loss of 17 cents per share was wider than the Zacks Consensus Estimate of a loss of 10 cents.
Morgan Stanley and American Finance Association Announce Stephen A. Ross as Recipient of the 2014 Award for Excellence in Finance
Business Wire - Fri Feb 07, 9:00AM CST
Morgan Stanley (NYSE:MS) and the American Finance Association (AFA) are pleased to announce Stephen A. Ross, the Franco Modigliani Professor of Financial Economics at the MIT Sloan School of Management, is the recipient of the Morgan Stanley-AFA 2014 Award For Excellence in Finance. As part of the award, Professor Ross receives a $200,000 cash grant which he will donate in equally divided funds to the California Institute of Technology and the Foundation for the Advancement of Research in Financial Economics.
AMAG Provides Business Outlook for 2014 and Reports 2013 Financial Results
GlobeNewswire - Thu Feb 06, 6:00AM CST
-- Achieves record annual U.S. Feraheme product revenues in 2013 with 28% growth over 2012
Concise Analysis of the International Intravenous (IV) Iron Drugs Industry
M2 - Tue Mar 11, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8bxct/intravenous_iv) has announced the addition of the "Concise Analysis of the International Intravenous (IV) Iron Drugs Industry" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 20 companies including many key and niche players such as: - Actavis, Inc. - AMAG Pharmaceuticals, Inc. - Fresenius Medical Care AG & Co. - KGaA Galenica Ltd. - Vifor Pharma Ltd. - Luitpold Pharmaceuticals, Inc. - American Regent, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview & Trends 3. Regulatory Overview 4. Overview Of Intravenous (Iv) Iron Drugs 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 20 (including Divisions/Subsidiaries - 22) - The United States (8) - Japan (2) - Europe (4) - Germany (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (8) For more information visit http://www.researchandmarkets.com/research/k8...avenous_iv
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Shares of AMAG Down 12.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 9:33AM CST
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 4 months, AMAG Pharmaceuticals has returned 12.64% as of today's recent price of $21.11.
AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 34th Annual Healthcare Conference
GlobeNewswire - Thu Feb 27, 8:52AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Cowen and Company 34 Annual Healthcare Conference on Monday, March 3, 2014 at 4:10 p.m. ET in Boston. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed.
AMAG Pharmaceuticals names Edward Jordan as SVP of Sales and Marketing
M2 - Wed Feb 26, 3:16AM CST
Pharmaceutical company AMAG Pharmaceuticals (NasdaqGS:AMAG) reported on Tuesday the election of Edward Jordan as senior vice president of its sales and marketing.
AMAG Pharmaceuticals Appoints Edward Jordan as Senior Vice President of Sales and Marketing
GlobeNewswire - Tue Feb 25, 7:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Edward Jordan as senior vice president of sales and marketing. Mr. Jordan brings to AMAG more than 20 years of experience in U.S. and international pharmaceutical sales and marketing operations. Prior to joining AMAG, Mr. Jordan served as head of sales, marketing, and operations of the women's health division at Teva Pharmaceuticals. In this role he led sales, marketing, training, and sales analytics for their branded pharmaceuticals, over-the-counter products and a medical device.
Mintz Levin Named Biotechnology "Law Firm of the Year- North America" by M&A Today Global Awards
Business Wire - Fri Feb 21, 11:46AM CST
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. announced that it has been recognized by M&A Today's Global Awards as the 2014 "Law Firm of the Year (Biotechnology) - North America." M&A Today's Global Awards program identifies "industry leaders, exemplary teams and distinguished organizations, based on the simple principles of veracity, accuracy and insight."
Study Shows MuGard(R) is More Effective Than Sham-Control at Reducing Mouth and Throat Soreness Associated With Oral Mucositis in Head and Neck Cancer Patients
GlobeNewswire - Tue Feb 18, 7:01AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the publication of data from a multi-institutional trial of MuGard in the online edition of the journal Cancer available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.28553/full. MuGard is a mucoadhesive hydrogel. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing pain associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.
AMAG Pharmaceuticals Has Returned 19.9% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Thu Feb 13, 9:24AM CST
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 3 months, AMAG Pharmaceuticals has returned 19.93% as of today's recent price of $19.35.
Spanning and CloudLock to Present "How to Prevent Data Loss and Ensure Compliance for Your SaaS Applications"
Business Wire - Thu Feb 13, 8:00AM CST
Spanning Cloud Apps, the leading provider of data backup and recovery for cloud applications, will join CloudLock, the cloud security pioneer and the world's leading cloud data security company, to demonstrate how organizations can proactively take control of their SaaS applications, preventing data loss and maintaining security and compliance. The webinar, "How to Prevent Data Loss and Ensure Compliance for Your SaaS Applications," will feature AMAG Pharmaceuticals. The company will explain how they effectively implemented backup and recovery for Google Apps and are enforcing data loss prevention policies in Google Drive. Attendees will learn how to mitigate the risks of data leakage and loss, while improving business continuity.
AMAG Pharmaceuticals (AMAG) Falls: Crumbles 5.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:38AM CST
AMAG Pharmaceuticals, Inc. (AMAG) saw a big move last session, as the company’s shares fell by more than 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for AMAG, as the stock is now down roughly 13% since Jan 15.
AMAG Pharmaceuticals Announces Pricing of $175 Million of 2.50% Convertible Senior Notes Due 2019
GlobeNewswire - Wed Feb 12, 5:00AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the pricing of $175 million aggregate principal amount of 2.50% Convertible Senior Notes due 2019 (the "notes") in an underwritten public offering (the "offering") registered under the Securities Act of 1933, as amended. The size of the transaction was increased from the previously announced aggregate principal amount of $150 million. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as book-running managers and Cowen and Company, LLC and Robert W. Baird & Co. Incorporated are acting as co-managers for the offering. AMAG has granted the underwriters the option to purchase, exercisable within a 30-day period, up to an additional $25 million principal amount of notes solely to cover over-allotments, if any. The offering is expected to close on February 14, 2014, subject to customary closing conditions.
Survey Says: Voicemail-to-Text Service Brings the Speed and Convenience to Voice Messaging that Consumers Want
Business Wire - Tue Feb 11, 7:00AM CST
Nuance Communications, Inc. (NASDAQ:NUAN) today announced the results of a recently commissioned third-party survey conducted by Research Now that explores text messaging and voicemail habits of mobile smartphone users. Taking a closer look at how people prefer to stay in touch, the survey revealed that users are seeking ways to ensure their messages are received promptly every time for both text and voice messaging. The survey revealed that, given a choice, 62 percent of people would most likely switch to a voice-to-text messaging system from a traditional voicemail system to stay better connected on the go.
AMAG Pharmaceuticals Announces Proposed Offering of $150 Million of Convertible Senior Notes due 2019
GlobeNewswire - Mon Feb 10, 3:07PM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of Convertible Senior Notes due 2019 (the "notes") in an underwritten public offering (the "offering") registered under the Securities Act of 1933, as amended. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as book-running managers for the offering. AMAG expects to grant the underwriters an option to purchase, exercisable within a 30-day period, up to an additional $22.5 million principal amount of notes, solely to cover over-allotments, if any.
AMAG Pharmaceuticals, Inc. to Participate in the Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 10, 8:39AM CST
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will participate in an analyst-led fireside chat at the Leerink Global Healthcare Conference in New York, NY. The fireside chat will take place on Wednesday, February 12, 2014 at 8:00 a.m. ET and will include a discussion on the company's business, regulatory status, strategy and growth prospects.
Wider-than-Expected Q4 Loss at AMAG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 9:40AM CST
AMAG's fourth quarter 2013 loss of 17 cents per share was wider than the Zacks Consensus Estimate of a loss of 10 cents.
Morgan Stanley and American Finance Association Announce Stephen A. Ross as Recipient of the 2014 Award for Excellence in Finance
Business Wire - Fri Feb 07, 9:00AM CST
Morgan Stanley (NYSE:MS) and the American Finance Association (AFA) are pleased to announce Stephen A. Ross, the Franco Modigliani Professor of Financial Economics at the MIT Sloan School of Management, is the recipient of the Morgan Stanley-AFA 2014 Award For Excellence in Finance. As part of the award, Professor Ross receives a $200,000 cash grant which he will donate in equally divided funds to the California Institute of Technology and the Foundation for the Advancement of Research in Financial Economics.
AMAG Provides Business Outlook for 2014 and Reports 2013 Financial Results
GlobeNewswire - Thu Feb 06, 6:00AM CST
-- Achieves record annual U.S. Feraheme product revenues in 2013 with 28% growth over 2012
